Abstract
The term “disease modifying drugs” (DMD) is taken from rheumatologists who coined it after the use of immunosuppressive drugs and, more recently, the association of “biological drugs” that changed the degenerative course of rheumatic disease.
In the treatment of multiple sclerosis (MS), the advent of interferon (IFN)-β, which caused a reduction in the number of relapses and possibly improvement in disability outcomes, was the first strategy to prevent inflammatory damage in the central nervous system (CNS). Soon after, glatiramer acetate showed similar results. It would be more than a decade before natalizumab was licensed, showing a much better efficiency in relapse reduction than was seen after first-line therapies failed. The pipeline is now much larger with several drugs on the horizon. Overall, the anti-inflammatory strategy has been mostly successful but drugs that have protection and repair mechanisms are still missing.
Keywords: Multiple sclerosis, treatments, mechanisms of action.
CNS & Neurological Disorders - Drug Targets
Title:Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
Volume: 11 Issue: 5
Author(s): Monica Marta and Gavin Giovannoni
Affiliation:
Keywords: Multiple sclerosis, treatments, mechanisms of action.
Abstract: The term “disease modifying drugs” (DMD) is taken from rheumatologists who coined it after the use of immunosuppressive drugs and, more recently, the association of “biological drugs” that changed the degenerative course of rheumatic disease.
In the treatment of multiple sclerosis (MS), the advent of interferon (IFN)-β, which caused a reduction in the number of relapses and possibly improvement in disability outcomes, was the first strategy to prevent inflammatory damage in the central nervous system (CNS). Soon after, glatiramer acetate showed similar results. It would be more than a decade before natalizumab was licensed, showing a much better efficiency in relapse reduction than was seen after first-line therapies failed. The pipeline is now much larger with several drugs on the horizon. Overall, the anti-inflammatory strategy has been mostly successful but drugs that have protection and repair mechanisms are still missing.
Export Options
About this article
Cite this article as:
Marta Monica and Giovannoni Gavin, Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon, CNS & Neurological Disorders - Drug Targets 2012; 11 (5) . https://dx.doi.org/10.2174/187152712801661301
DOI https://dx.doi.org/10.2174/187152712801661301 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Latent Viral Infections in Mechanically Ventilated Patients
Current Respiratory Medicine Reviews Drug Trials in Dementia: Challenging Ethical Dilemmas
Current Alzheimer Research Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Genomic Databases and the Search of Protein Targets for Protozoan Parasites
Current Drug Targets Meet Our Editorial Board Member
Clinical Cancer Drugs Non-Replicating Viral Vector-Based AIDS Vaccines: Interplay Between Viral Vectors and the Immune System
Current HIV Research Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Pharmaceutical Design Small Non-Coding RNAs as Biomarkers
Recent Patents on Biomarkers Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Application of Alphaviral Vectors for Immunomodulation in Cancer Therapy
Current Pharmaceutical Design Pan-Vertebrate Toll-Like Receptors During Evolution
Current Genomics Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry In Silico Stereo-Electronic Analysis of PMD (p-Menthane-3-8-Diol) and its Derivatives for Pharmacophore Development May Aid Discovery of Novel Insect Repellents
Current Computer-Aided Drug Design Infectious Agents and Neurodegenerative Diseases: Exploring the Links
Current Topics in Medicinal Chemistry Interleukin-18, From Neuroinflammation to Alzheimers Disease
Current Pharmaceutical Design Plasmid DNA Manufacturing Technology
Recent Patents on Biotechnology Disorders of Consciousness and Pharmaceuticals that Act on Oxygen Based Amino Acid and Monoamine Neurotransmitter Pathways of the Brain
Current Pharmaceutical Design Biological and Pharmacological Activities of Iridoids: Recent Developments
Mini-Reviews in Medicinal Chemistry Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued)